FDC Ltd
FDC Q3 FY23: Revenue ₹407 Cr, PAT ₹41 Cr
Q3 FY23 investor presentation: what the company reported on revenue, margins and projects.
Based on FDC Ltd's Q3 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). EBITDA for Q3FY23: ₹65 crore, up 15% YoY from ₹57 crore in Q3FY22 - Operating Expenses for Q3FY23: ₹360 crore, up 21% YoY from ₹298 crore in Q3FY22 - Profit After Tax (PAT) for Q3FY23: ₹41 crore, up 26% YoY from ₹32 crore in Q3FY22 - Revenue from operations for Q3FY23: ₹407 crore, up 19% YoY from ₹341 crore in Q3FY22 - EPS for Q3FY23: ₹2.38, up 27% YoY from ₹1.87 in Q3FY22 - Operating margin or explicit margin outlook is not explicitly stated in the presentation pages provided.
From FDC Ltd's Q3 FY23 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13).
- Total Income Q3FY23: ₹425 crores, up 20% YoY from ₹354 crores (Page 13).
- Domestic sales Q3FY23: ₹318 crores with 10% YoY growth (Page 4).
- Export sales Q3FY23: ₹92 crores with 71% YoY growth (Page 4).
- Quarterly sales trend shows 19% YoY growth in Q3FY23 vs Q3FY22 (Page 12).
2 more points management made on revenue & sales performance
Profitability & Margins
See what FDC Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what FDC Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
FDC Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹585 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What FDC Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q3 FY23)
138.73 Cr, up 21% QoQ (from Rs. Key concall takeaways from Anuh Pharma Ltd's Q3 FY23 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were FDC Ltd Q3 FY23 results?
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). EBITDA for Q3FY23: ₹65 crore, up 15% YoY from ₹57 crore in Q3FY22 - Operating Expenses for Q3FY23: ₹360 crore, up 21% YoY from ₹298 crore in Q3FY22 - Profit After Tax (PAT) for Q3FY23: ₹41 crore, up 26% YoY from ₹32 crore in Q3FY22 - Revenue from operations for Q3FY23: ₹407 crore, up 19% YoY from ₹341 crore in Q3FY22 - EPS for Q3FY23: ₹2.38, up 27% YoY from ₹1.87 in Q3FY22 - Operating margin or explicit margin outlook is not explicitly stated in the presentation pages provided.
What is FDC Ltd share price analysis?
FDC Ltd currently shows a neutral. The stock trades at a P/E of 18.6 with a market cap of ₹5,739 Cr. Investors should review the full earnings analysis for detailed insights.
Is FDC Ltd planning capital expenditure?
The investor presentation does not explicitly detail any capex, capacity expansion, new plant, or project specifics with amounts, status, or timelines.
Keep FDC Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.